Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum

Table 1 Demographics, characteristics, and molluscum history of participants^a,b

See More Characteristics	Pooled CAMP-1 and CAMP-2
See More Characteristics	VP-102 (N = 310)	Vehicle (N = 218)
Age, years
Mean	7.5 ± 6.7	6.8 ± 5.8
Median	6.0	6.0
Range	2–60	2–54
Age group, years
≥ 2–5	137 (44.2)	106 (48.6)
≥ 6–11	140 (45.2)	89 (40.8)
≥ 12–18	22 (7.1)	18 (8.3)
≥ 19	11 (3.5)	5 (2.3)
Sex
Female	154 (49.7)	107 (49.1)
Male	156 (50.3)	111 (50.9)
Race or ethnic group
White	277 (89.4)	202 (92.7)
Black or African American	13 (4.2)	8 (3.7)
Asian	6 (1.9)	1 (0.5)
American Indian/Alaskan Native	0	1 (0.5)
Other	14 (4.5)	6 (2.8)
Time since clinical diagnosis (days)
Mean	122.9 ± 200.9	126.2 ± 198.7
Median	25.0	31.5
Range	1–1247	1–1302
Previous treatment for molluscum
Yes	89 (28.7)	72 (33.0)
AD
Diagnosis of AD	50 (16.1)	35 (16.1)
Active AD^a	23 (7.4)	20 (9.2)
Baseline lesion count
Mean	20.5 ± 23.1	22.5 ± 22.3
Median	12.0	15.5
Range	1–184	1–110

Data are presented as mean ± standard deviation or N (%) unless otherwise indicated
AD atopic dermatitis, PDE-4 phosphodiesterase-4
^aActive AD was determined by concomitant medications during the study, including topical calcineurin inhibitors, topical steroids, and topical PDE-4 inhibitors
^bIntent-to treat population